QCT Announces Support of NVIDIA Grace CPU Superchips for Use in HPC and AI Applications
24.5.2022 07:00:00 EEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced new servers that will support the NVIDIA Grace™ CPU Superchip and Grace™ Hopper™ Superchip. QCT is incorporating the NVIDIA Grace™ CPU, striving for the highest performance, memory bandwidth, energy efficiency and configurability that is ready for the modern data center and addresses the most demanding artificial intelligence (AI), high-performance computing (HPC), data analytics, digital twins, cloud gaming, and hyperscale computing applications.
Breakthrough CPU for the Modern Data Center
The NVIDIA Grace CPU Superchip is a breakthrough processor designed for the modern data center, providing the highest performance and twice the memory bandwidth and energy-efficiency compared to today’s leading server processors. The NVIDIA Grace CPU Superchip can be used standalone or with NVIDIA’s industry-leading GPU and BlueField® data processing unit (DPU) building blocks. The Grace Hopper Superchip pairs an NVIDIA Grace CPU with an NVIDIA Hopper architecture-based GPU. The integrated module is designed to serve HPC and giant-scale AI applications. The NVIDIA Grace Hopper Superchip will enable up to 10x higher performance in a variety of configurations for applications running terabytes of data, enabling scientists and researchers to reach unprecedented solutions to the world’s most complex problems.
“As a leading cloud enabler, QCT is committed to being a critical enabler for AI and HPC applications for the modern data center,” said Mike Yang, President of QCT. “We are thrilled to broaden our compute portfolio with the NVIDIA Grace CPU Superchip and Grace Hopper Superchip. As we are seeing a rise in the multitude of AI applications, QCT works closely with NVIDIA to ensure our clients can benefit from the latest and greatest CPU, GPU and networking technologies.”
QCT will add the new NVIDIA Grace CPU Superchip and Grace Hopper Superchip to its extensive server portfolio to deliver unprecedented accelerated computing. Designed to interface with the latest PCIe Gen5 protocol, this will be the fastest communication to enable optimal connectivity with the highest-performing GPUs, and the fastest networking with up to 400 gigabits per second (Gb/s) Ethernet or NVIDIA Quantum-2 400Gb/s InfiniBand with NVIDIA ConnectX®-7 smart network interface cards (SmartNICs) and BlueField-3 DPUs to provide best-in-class acceleration for secure HPC and AI workloads. These new QCT server systems will be released next year and will also support NVIDIA’s computing software stacks, including NVIDIA HPC, NVIDIA AI, Omniverse and NVIDIA RTX.
Follow QCT on Facebook and Twitter to receive the latest news and announcements.
About QCT
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.qct.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005375/en/
Contact information
Danny Chang
danny_chang@quantatw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom